Humanigen, Inc.
https://www.humanigen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Humanigen, Inc.
Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success
Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.
InflaRx Looks Ahead To Late 2023 Commercial Sales For COVID-19 Antibody
The price will be more expensive than prior COVID-19 antibodies, reflecting its target to critically ill patients who are hospitalized.
Humanigen Isn’t Throwing In The Towel On Lenzilumab For COVID-19 Just Yet
The company is assessing a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity.
Publisher’s Spotlight: Citeline Awards Honor R&D Excellence
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- KaloBios Pharmaceuticals, Inc.
- Humanigen Australia Pty Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice